Supernus

Supernus’ stocks down again, despite positive phase 3 ADHD data

Supernus’ two phase 3 studies in children with ADHD hit their primary endpoints but didn’t wow investors worried about established generics.

Conor Hale Dec 6, 2018 11:23am

Supernus adds epilepsy drug via $185M Biscayne buy

Sep 14, 2018 9:45am

Supernus clears PhII ADHD drug hurdle, but shares drip downward

Oct 11, 2016 11:40am